Recurrence of anti-GBM disease 8 years after renal transplantation

Khandelwal, Mamta

doi:10.1093/ndt/gfg393

Cited by 35 publications

(22 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with AASV-induced end-stage renal disease who are fortunate enough to receive a kidney transplant still have a risk of recurrence [30]. In comparison, the risk of recurrence of Goodpasture’s disease after treatment is rare [31] with only five cases of recurrent GBM disease in renal transplant patients [32]. Alternative treatments are also available for persisting, relapsing or refractory disease in AASV but are nonexistent in Goodpasture’s disease.…”

Section: Discussionmentioning

confidence: 99%

Antibody-negative Goodpasture's disease

Stolk¹,

Carl²,

Massey

2010

Clinical Kidney Journal

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Antibody-negative Goodpasture's disease

Stolk¹,

Carl²,

Massey

2010

Clinical Kidney Journal

View full text Add to dashboard Cite

“…None of the 10 patients undergoing transplantation for anti‐GBM disease displayed recurrence in the graft within a mean follow‐up period of 62 months [110]. According to previous case reports, the mean time interval from transplantation to recurrence is 5 months to 12 years [111]. Renal biopsy specimens typically show crescentic glomerulonephritis on histologic analysis.…”

Section: Secondary Glomerulonephritismentioning

confidence: 99%

Recurrence from primary and secondary glomerulopathy after renal transplant

Canaud¹,

Audard²,

Kofman³

et al. 2012

Transplant International

View full text Add to dashboard Cite

Summary Glomerulonephritis is the primary cause of end‐stage renal failure in 30–50% of kidney transplant recipients and recurrence of the initial disease is an important determinant of long‐term graft outcome after transplantation. Although renal transplantation remains the best treatment option for patients with end stage renal diseases in most cases, diagnosis and management of recurrences of glomerulopathies are critical for the optimization and improvement of long‐term kidney transplant graft survival and provide a unique opportunity to explore the pathogenesis of native kidney disease. This review aims to update knowledge for a large panel of recurrent primary and secondary glomerulonephritis after kidney transplantation, excluding diabetic nephropathy including primary focal and segmental glomerulosclerosis, membranous nephropathy, IgA nephropathy, membranoproliferative glomerulonephritis, lupus, vasculitis but also less usual secondary nephropathy related to sarcoidosis, AA and AL amyloidosis, monoclonal immunoglobulin deposition disease, and fibrillary glomerulonephritis.

show abstract

“…We have used both rituximab and cyclophosphamide in these cases and rates of antibody decline appear similar, however, they are significantly faster when combined with plasmapheresis. Although no comparison trials are available we suggest six months of anti-GBM antibody negativity prior to transplantation, and this strategy has resulted in no cases of recurrent disease in our transplant populations, although very rare cases have previously been reported (61) in which other provoking factors may have contributed. …”

Section: Immunosuppressionmentioning

confidence: 90%

Diagnostic and management challenges in Goodpasture’s (anti-glomerular basement membrane) disease

Henderson

Salama

2017

Nephrology Dialysis Transplantation

View full text Add to dashboard Cite

Goodpasture's or anti-glomerular basement membrane (GBM) disease is classically characterised by the presence of circulating autoantibodies directed against the non-collagenous domain of the 3 chain of type IV collagen(3(IV)NC1), targeting glomerular and alveolar basement membranes, and associated with rapidly progressive crescentic glomerulonephritis, with alveolar haemorrhage in over half the patients. However, there are increasing examples of variants or atypical presentations of this disease, and proposed novel therapeutic options, which nephrologists should be aware of. The pathophysiology of this condition has been understood through molecular analysis of the antibody-antigen interactions and the use of HLA-transgenic animals, while the association of anti-GBM antibodies with anti-neutrophil cytoplasm antibodies (ANCA) and their combined impact on disease phenotype is increasingly recognised, providing some insights into the basis of glomerular damage and autoimmunity.

show abstract

Recurrence of anti-GBM disease 8 years after renal transplantation

Cited by 35 publications

References 6 publications

Antibody-negative Goodpasture's disease

Antibody-negative Goodpasture's disease

Recurrence from primary and secondary glomerulopathy after renal transplant

Diagnostic and management challenges in Goodpasture’s (anti-glomerular basement membrane) disease

Contact Info

Product

Resources

About